CTN 239
Studies
The CTN+ supports clinical trials, implementation science projects, and non-interventional research of the highest scientific and ethical standards.
-
CTN 239: Phase II study of AGS-004 an immunotherapeutic agent in combination with ART followed by ART interruption
A phase II study testing the activity and safety of AGS-004 as an immunotherapeutic in successfully ART-treated subjects infected with HIV-1 in combination with ART followed by ART interruption: Trial results
Publications
Our researchers and trainees have produced hundreds of peer-reviewed publications in a wide range of HIV- and STBBI-related areas.
Careers
Interested in joining our team? Here are the current career opportunities with the CTN+ and our collaborators. For Fellowship opportunities, please visit our Postdoctoral Fellowship program page.
Learn More